Navigation Links
Eurand to Present Zentase Phase III Data

MILAN, Italy, and DAYTON, Ohio, June 08, 2007 /PRNewswire-FirstCall/ --Eurand to present data on Zentase at European Cystic Fibrosis Society Annual Meeting. .

-- Exocrine pancreatic insufficiency (EPI) is a deficiency of digestive

enzymes normally produced by the pancreas that can result from a number

of diseases, including cystic fibrosis, chronic pancreatitis, and

pancreatic cancer


-- EPI results in poor digestion and reduced absorption of nutrients

which, if untreated, can lead to impaired growth in children, impaired

immune response and shortened life expectancy


-- Treatment with pancreatic replacement products replaces enzymes lost

through this disease. Other than enzyme replacement, no known

alternative therapy for the loss of digestive enzymes is currently

available


-- Eurand completed two phase III clinical trials on its lead product

candidate, Zentase(TM), for the treatment of EPI


-- Eurand expects to initiate a rolling submission of its new drug

application (NDA) with the US Food and Drug Administration (FDA) for

Zentase for the treatment of EPI in the 2nd quarter of this year


-- Posters 243-246 will be presented on June 15th between 1:30-2:30pm:


1. Zentase, a New Pancreatic Enzyme Product (PEP), Is Safe and

Effective in Cystic Fibrosis (CF) Patients with Exocrine Pancreatic

Insufficiency (EPI)

2. Zentase, a New Pancreatic Enzyme Product (PEP), in Young Cystic

Fibrosis (CF) Patients with Exocrine Pancreatic Insufficiency (EPI)
< br /> 3. Child friendly dosing options for PEPs

4. Overfilling in Current Pancreatic Enzyme Products (PEPs): Still an

Unresolved Issue


For more information on Zentase and Eurand

Contact: Marian Cutler, Eurand, +1-973-517-0519

This media alert, and oral statements made with respect to information contained in this release, constitutes forward-looking statements. Such forward-looking statements include those which express plan, anticipation, intent, contingency, goals, targets or future development and/or otherwise are not statements of historical fact including, but not limited to Eurand's plans for our NDA filing, enrollment and future plans for our clinical trials, progress of and reports of results from clinical studies, clinical development plans and product development activities. The words "expect" and similar expressions also identify forward-looking statements. These statements are based upon management's current expectations and are subject to risks and uncertainties, known and unknown, which could cause actual results and developments to differ materially from those expressed or implied in such statements. Factors that could affect actual results include risks associated with the possibility that the FDA refuses to approve our NDA; the outcome of any discussions with the FDA; and unexpected delays in preparation of materials for submission to the FDA as apart of our NDA filing. Forward looking statements contained in this press release are made as of this date, and we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Actual events could differ materially from those anticipated in the forward- looking statements.

CONTACT: Marian Cutler of Eurand, +1-973-517-0519

Web site: http://www.eurand.com/

Ticker Symbol: (:EURX)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Eurands Zentase Effective in Treating Exocrine Pancreatic Insufficiency, Studies Show
2. Eurand Announces Positive Phase III Clinical Study Results
3. The Past, Present and Future of HLA Typing
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
7. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
8. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
9. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
10. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2017)... Mich. , Sept. 18, 2017  PMD Healthcare ... Specialty Pharmacy of Kalamazoo, Mich. , ... hub service that expedites and streamlines patient and provider ... PD 2.0, and wellness management services.  ... device used to measure lung function for a variety ...
(Date:9/12/2017)... and NEW YORK , Sept. 12, 2017 /PRNewswire/ ... ratings for global supply chains, has published the first annual edition of ... performance of more than 20,400 companies evaluated by EcoVadis, based on Scorecard ... and 2016. ... Global CSR Risk & Performance Index ...
(Date:9/9/2017)... 8, 2017 ... Unit coming to Washington DC ... When: Tuesday, September 12 th – Monday, September 18 th .The ... free MRI brain scans to the public.Where:  BTF,s ... at 501 K Street NW, Washington, D.C.What:BTF brings its nationwide initiative, the ...
Breaking Medicine Technology:
(Date:9/22/2017)... ... September 22, 2017 , ... After a long ... finds a new lease on life with assistance from CreditAssociates. CreditAssociates provides debt ... problem with unsecured debt. The senior is one of the satisfied clients who ...
(Date:9/22/2017)... ... September 22, 2017 , ... SABRE ... Scholarship Sweepstakes.,  , Molli C., a graduate student from Sonora, California, who will ... Administration at St. Thomas University in Miami, Florida, was selected from a pool ...
(Date:9/22/2017)... ... September 22, 2017 , ... Pullano Law Offices, a Chicago personal injury law ... been selected to serve as President of the North Suburban Bar Association for 2017-2018. ... Dinner hosted by the NSBA at the North Shore Country Club in Glenview, IL, ...
(Date:9/22/2017)... , ... September 22, 2017 , ... ... nutritional supplement produced by Native Remedies that helps promote pancreatic health and ... many individuals. However, some prescription-based approaches can have negative side effects, and with ...
(Date:9/22/2017)... ... 22, 2017 , ... "Success Files," a short- and long-form ... is a disease estimated to affect the lives of more than 5 million ... Association, a leading voice in the fight for cure and research into the ...
Breaking Medicine News(10 mins):